Clinical utility of a pharmacostatistical model for Ibandronate in postmenopausal osteoporosis

Current Drug Metabolism

Volumn 7, Issue 7, 2006, Pages 827-836

  Reginster, J Y ^a,c   Gieschke, R ^b  

^a WHO Collaborating Center for Public Health Aspects of Rheumatic Diseases   (Belgium)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Ibandronate; Modeling; Osteoporosis; Pharmacodynamics; Pharmacokinetics; Simulation

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; ETIDRONIC ACID; IBANDRONIC ACID; OLPADRONIC ACID; OSTEOCALCIN; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

ACCURACY; BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; COMPARTMENT MODEL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG URINE LEVEL; FRAGILITY FRACTURE; HUMAN; MATHEMATICAL MODEL; PHARMACODYNAMICS; POSTMENOPAUSE OSTEOPOROSIS; PREDICTION; REVIEW; RISK REDUCTION; SIMULATION; VALIDATION STUDY; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION;

BONE DENSITY CONSERVATION AGENTS; COMPUTER SIMULATION; DIPHOSPHONATES; FEMALE; HUMANS; MODELS, BIOLOGICAL; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 33749425269     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920006778520624     Document Type: Review

References (78)

1. Kauffman, W.J. and Smarr, L.L. (1993) Supercomputing and the transformation of science. Scientific American Library, New York.
2. Johnson, S. (1998) Drug Inf. J., 32, 961-969.
3. Reigner, B.B.; Williams, P.E.; Patel, I.H.; Steimer, J.L.; Peck, C. and Van Brummelen, P. (1997) Clin. Pharmacokinet., 33, 142-152.
4. Gieschke, R. and Steimner, J.L. (2000) Eur. J. Drug Metab. Pharmacokinet., 25, 49-58.
5. Holford, N.H.; Kimko, H.C.; Monteleone, J.P. and Peck, C.C. (2000) Annu. Rev. Pharmacol. Toxicol., 40, 209-234.
6. Sheiner, L.B. and Steimer, J.L. (2000) Annu. Rev. Pharmacol. Toxicol., 40, 67-95.
7. Goggin, T.; Gieschke, R.; Pillai, G.; Fotteler, B.; Jordan, P. and Steimer, J.L. (2002) in Simulation for Designing Clinical Trials: a Pharmacokinetic-Pharmacodynamic Modelling Perspective (Kimko, H. and Duffull, S.B. Eds.), Marcel Dekker, New York.
8. Gieschke, R.; Reigner, B.G. and Steimer, J.L. (1997) Int. J. Clin. Pharmacol. Ther., 35, 469-474.
9. Hale, M.D.; Nicholls, A.J. and Bullingham, R.E. (1998) Clin. Pharmacol. Ther., 64, 672-683.
10. Veyrat-Follet, C.; Bruno, R.; Olivares, R.; Rhodes, G.R. and Chalkin, P. (2000) Clin. Pharmacol. Ther., 68, 677-687.
11. Ravn, P.; Neugebauer, G. and Christiansen, C. (2002) Bone, 30, 320-324.
12. Boeckmann, A.J.; Sheiner, L.B. and Beal, S.L. (1984) NONMEM User Guide, Part V, NONMEM Project Group, University of California, San Francisco.
13. Dayneka, N.L.; Garg, V. and Jusko, W.J. (1993) J. Pharmacokinet. Biopharm., 21, 457-478.
14. Gabrielsson, J.; Jusko, W.J. and Alari, L. (2000) Biopharm. Drug Dispos., 2, 41-52.
15. Sheiner, L.B.; Stanski, D.R.; Vozeh, S.; Miller, R.D. and Ham, J. (1979) Clin. Pharmacol. Ther., 25, 358-371.
16. American Association of Clinical Endocrinologists (AACE). (2003) Endocr. Pract., 9, 544-564.
17. Consensus Development Conference (1993) Am. J. Med., 94, 646-650.
18. Riggs, B.L. and Melton 3rd, L.J. (1992) N. Eng. J. Med., 327, 620-627.
19. Russell, R.G.; Croucher, P.I. and Rogers, M.J. (1999) Osteoporos. Int., 9, S66-S80.
20. Bauss, F. and Russell, R.G.G. (2004) Osteoporos. Int., 15, 423-433.
21. Rogers, M.J.; Gordon, S.; Benford, H.L.; Coxon, F.P.; Luckman, S.P.; Monkkonen, J. and Frith, J.C. (2000) Cancer, 88, 2961-2978.
22. Currey, J.D. (1986) N. Eng. J. Med., 15, 153-154.
23. Marshall, D.; Johnell, O. and Wedel, H. (1996) BMJ, 312, 1254-1259.
24. Wasnich, R.D. and Miller, P.D. (2000) J. Clin. Endocrinol. Metab., 85, 231-236.
25. Cummings, S.R.; Karpf, D.B.; Harris, F.; Genant, H.K.; Ensrud, K.; LaCroix, A.Z. and Black, D.M. (2002) Am. J. Med., 112, 281-289.
26. Hochberg, M.C.; Greenspan, S.; Wasnich, R.D.; Miller, P.D.; Thompson, D.E. and Ross, P.D. (2002) J. Clin. Endocrinol. Metab., 87, 1586-1592.
27. Delmas, P.D.; Eastell, R.; Garnero, P.; Seibel, M.J. and Stepan, J. (2000) Osteoporos. Int., 11 (Suppl. 8), S2-S17.
28. Eastell, R.; Barton, I.; Hannon, R.A.; Chines, A.; Garnero, P. and Delmas, P.D. (2003) J. Bone Miner. Res., 18, 1051-1056.
29. Eastell, R.; Baumann, M.; Hoyle, N.R. and Wieczorek, L. (2001) Bone Markers: Biochemical and Clinical Perspectives, Martin Dunitz, London.
30. Ettinger, B.; Pressman, A.; Schein, J.; Chan, J.; Silver, P. and Connolly, N. (1998) J. Managed Care Pharm., 4, 488-492.
31. Recker, R.R.; Gallagher, R. and MacCosbe, P.E. (2005) Mayo. Clin. Proc., 80, 856-861.
32. Cramer, J.A.; Amonkar, M.M.; Hebborn, A. and Altman, R. (2005) Curr. Med. Res. Opin., 21. 1453-1460.
33. Simon, J.A.; Lewiecki, E.M.; Smith, M.E.; Petruschke, R.A.; Wang, J.L. and Palmisano, J.J. (2002) Clin. Ther., 24, 1871-1886.
34. Kendler, D.; Kung, A.W.; Fuleihan, Gel-H.; Gonzalez Gonzalez, J.G.; Gaines, K.A.; Verbruggen, N. and Melton, M.E. (2004) Maturitas, 48, 243-251.
35. Simon, J.A.; Beusterien, K.M.; Hebborn, A. and Leidy, N.K. (2005) The Female Patient, 30, 31-36.
36. Mühlbauer, R.C.; Bauss, F.; Schenk, R.; Janner, M.; Bosies, E.; Strein, K. and Fleisch, H. (1991) J. Bone Miner. Res., 6, 1003-1011.
37. Chesnut III, C.H.; Skag, A.; Christiansen, C.; Recker, R.; Stakkestad, J.A.; Hoiseth, A.; Felsenberg, D.; Huss, H.; Gilbride, J.; Schimmer, R.C. and Delmas, P.D. (2004) J. Bone Miner. Res., 19, 1241-1249.
38. Riis, B.J.; Ise, J.; Von Stein, T.; Bagger, Y. and Christiansen, C. (2001) J. Bone Miner. Res., 16, 1871-1878.
39. Miller, P.D.; McClung, M.R.; Macovei, L.; Stakkestad, J.A.; Luckey, M.; Bonvoisin, B.; Reginster, J.-Y.; Recker, R.R.; Hughes, C.; Lewiecki, E.M.; Felsenberg, D.; Delmas, P.D.; Kendler, D.L.; Bolognese, M.A.; Mairon, N. and Cooper, C. (2005) J. Bone Miner. Res., 20, 1315-1322.
40. Schnitzer, T.; Bone, H.G.; Crepaldi, G.; Adami, S.; McClung, D.; Kiel, D.; Felsenberg, D.; Recker, R.R.; Tonino, R.P.; Roux, C.; Pinchera, A.; Foldes, A.J.; Greenspan, S.L.; Levine, M.A.; Emkey, R.; Santora II, A.C.; Kaur, A.; Thompson, D.E.; Yates, J. and Orloff, J.J. (2000) Aging Clin. Exp. Res., 12, 1-12.
41. Brown, J.P.; Kendler, D.L.; McClung, M.R.; Emkey, R.D.; Adachi, H.D.; Bolognese, M.A.; Li, Z.; Balske, A. and Lindsay, R. (2002) Calcif. Tissue Int., 71, 103-111.
42. Cooper, C.; Emkey, R.D.; McDonald, R.H.; Hawker, G.; Bianchi, G.; Wilson, K. and Schimmer, R.C. (2003) J. Clin. Endocrinol. Metab., 88, 4609-4615.
43. Delmas, P.D.; Adami, S.; Strugala, C.; Stakkestad, J.A.; Reginster, J-Y.; Felsenberg, D.; Christiansen, C.; Civitelli, R.; Drezner, M.; Recker, R.R.; Bolognese, M.; Hughes, C.; Masanauskaite, D.; Ward, P.; Sambrook, P.; Reid, D.M. (2006) Arthritis Rheum., 54, 1838-1846.
44. FDA guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis (1994) www.fda.gov.
45. Barrett, J.; Worth, E.; Bauss, F. and Epstein, S. (2004) J. Clin. Pharmacol., 44, 951-965.
46. Reginster, J.-Y.; Wilson, K.M.; Dumont, E.; Bonvoisin, B. and Barrett, J. (2005) J. Clin. Endocrinol. Metab., 90, 5018-5024.
47. Bauss, F.; Endele, R.; Besenfelder, E. and Hoelck, J.-P. (2002) Calcif. Tissue Int., 70, 289-290.
48. Khan, S.A.; Kanis, J.A.; Vasikaran, S.; Kline, W.F.; Matsuzewski, B.K.; McCloskey, E.V.; Beneton, M.N.C.; Gertz, B.J.; Scribersras, D.G.; Holland, S.D.; Orgee, J.; Coombes, G.M.; Rogers, S.R. and Porras, A.G. (1997) J. Bone Miner. Res., 12, 1700-1707.
49. Hernandez, C.J.; Beaupré, G.S.; Marcus, R. and Carter, D.R. (2002) J. Bone Miner. Res., 17, 1662-1666.
50. Cremers, S.C.; Eekhoff, M.E.; Den Hartigh, J.; Hamdy, N.A.; Vermeij, P. and Papapoulos, S.E. (2003) J. Bone Miner. Res., 18, 868-875.
51. Cremers, S.; Den Sparidans, R.H.J.; Hamdy, N.; Vermeij, P. and Papapoulos, S. (2002) Eur. J. Clin. Pharmacol., 57, 883-890.
52. Mitchell, D.Y.; Eusebio, R.A.; Sacco-Gibson, N.A.; Pallone, K.A.; Kelly, S.C.; Nesbitt, J.D.; Brezovic, C.P.; Thompson, G.A. and Powell, J.H. (2000) J. Clin. Pharmacol., 40, 258-265.
53. Mitchell, D.Y.; Barr, W.H.; Eusebio, R.A.; Pallone Stevens, K.A.; Duke, F.P.; Russell, D.A.; Nesbitt, J.D.; Powell, J.H. and Thompson, G.A. (2001) Pharm. Res., 18, 166-170.
54. Chen, T.; Berenson, J.; Vescio, R.; Swift, R.; Gilchick, A.; Goodin, S.; LoRusso, P.; Ma, P.; Ravera, C.; Deckert, F.; Schran, H.; Seaman, J. and Skerjanec, A. (2002) J. Clin. Pharmacol., 42, 1228-1236.
55. Stepensky, D.; Kleinberg, L. and Hoffman, A. (2005) Clin. Pharmacokinet., 42, 863-881.
56. Defranoux, N.A.; Stokes, C.L.; Young, D.L. and Kahn, A.J. (2005) J. Bone Miner. Res., 20, 1079-1084.
57. Tayyar, S.; Weinhold, P.S.; Butler, R.A.; Woodard, J.C.; Zardiackas, L.D.; St John, K.R.; Bledsoe, J.M. and Gilbert, J.A. (1999) Bone, 25, 733-739.
58. Nyman, J.S.; Yeh, O.C.; Hazelwood, S.J. and Martin, R.B. (2004) Bone, 35, 296-305.
59. Heaney, R.P.; Yates, A.J. and Santora 2nd, A.C. (1997) J. Bone Miner. Res., 12, 1143-1151.
60. Hernandez, C.J.; Beaupré, G.S. and Carter, D.R. (2000) J. Rehabil. Res. Dev., 37, 235-244.
61. Hernandez, C.J.; Beaupré, G.S.; Marcus, R. and Carter, D.R. (2001) Bone, 29, 511-516.
62. Cremers, S.C.L.M.; Pillai, G. and Papapoulos, S. (2005) Clin. Pharmacokinet., 44, 551-570.
63. Heaney, R.P. (1994) J. Bone. Miner. Res., 9, 1515-1523.
64. Pillai, G.; Gieschke, R.; Goggin, T.; Jacqmin, P.; Schimmer, R.C. and Steimer, J.-L. (2004) Br. J. Clin. Pharmacol., 58, 618-631.
65. Jordan, P. and Gieschke, R. (2005) Comput. Methods Programs Biomed., 77, 91-97.
66. Recker, R.; Stakkestad, J.A.; Chesnut III, C.H.; Christiansen, C.; Skag, A.; Hoiseth, A.; Ettinger, M.; Mahoney, P.; Schimmer, R.C. and Delmas, P.D. (2004) Bone, 34, 890-899.
67. Adami, S.; Felsenberg, D.; Christiansen, C.; Robinson, J.; Lorenc, R.S.; Mahoney, P.; Coutant, K.; Schimmer, R.C. and Delmas, P.D. (2004) Bone, 34, 881-889.
68. Stakkestad, J.A.; Benevolenskaya, L.I.; Stepan, J.J.; Skag, A.; Nordby, A.; Oefijord, E.; Burdeska, A.; Jonkanski, I. and Mahoney, P. (2003) Ann. Rheum. Dis., 62, 969-975.
69. Thiébaud, D.; Burckhardt, P.; Kriegbaum, H.; Huss, H.; Mulder, H.; Juttmann, J.R. and Schöter, K.H. (1997) Am. J. Med., 103, 298-307.
70. Ravn, P.; Clemmensen, B.; Riis, B.J. and Christiansen, C. (1996) Bone, 19, 527-533.
71. Caro, J.J.; Ishak, K.J.; Huybrechts, K.F.; Raggio, G. and Naujoks, C. (2004) Osteoporos. Int. 15, 1003-1008.
72. Yood, R.A.; Emani, S.; Reed, J.I.; Lewis, B.E.; Charpentier, M. and Lydick, E. (2003) Osteoporos. Int., 14, 965-968.
73. Melton, L.J.; Atkinson, E.J.; Khosla, S.; Oberg, A.L. and Riggs, B.L. (2005) J. Bone Miner. Res., 20, 551-556.
74. Black, D.M.; Steinbuch, M.; Palermo, L.; Darget-Molina, P.; Lindsay, R.; Hoseyni, M.S. and Johnell, O. (2001) Osteoporos. Int., 12, 519-528.
75. FDA Advisory Committee for Pharmaceutical Science (2000) www.fda.gov.
76. FDA Guidance for Industry. Exposure-Response Relationships - Study design, data analysis, and regulatory applications (2003) www.fda.gov.
77. FDA Concept paper. End of Phase 2A meetings with sponsors regarding exposure-response of IND and NDA products (2003) www.fda.gov.
78. Peck, C.C.; Rubin, D.B. and Sheiner, L.B. (2003) Clin. Pharmacol. Ther., 73, 481-490.